JPS56167643A - Mannich base hydroxamic acid precursor drug for improving transmission of non-steroid antiinflammatory - Google Patents

Mannich base hydroxamic acid precursor drug for improving transmission of non-steroid antiinflammatory

Info

Publication number
JPS56167643A
JPS56167643A JP6073181A JP6073181A JPS56167643A JP S56167643 A JPS56167643 A JP S56167643A JP 6073181 A JP6073181 A JP 6073181A JP 6073181 A JP6073181 A JP 6073181A JP S56167643 A JPS56167643 A JP S56167643A
Authority
JP
Japan
Prior art keywords
chem
topical
carbamyl
hydroxamic acid
acid precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6073181A
Other languages
English (en)
Japanese (ja)
Other versions
JPH04982B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
Bii Suroon Kenesu
Ritoru Roi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JPS56167643A publication Critical patent/JPS56167643A/ja
Publication of JPH04982B2 publication Critical patent/JPH04982B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP6073181A 1980-04-24 1981-04-23 Mannich base hydroxamic acid precursor drug for improving transmission of non-steroid antiinflammatory Granted JPS56167643A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14352080A 1980-04-24 1980-04-24

Publications (2)

Publication Number Publication Date
JPS56167643A true JPS56167643A (en) 1981-12-23
JPH04982B2 JPH04982B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-01-09

Family

ID=22504442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6073181A Granted JPS56167643A (en) 1980-04-24 1981-04-23 Mannich base hydroxamic acid precursor drug for improving transmission of non-steroid antiinflammatory

Country Status (9)

Country Link
EP (1) EP0039051B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS56167643A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE14423T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3171467D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK156717C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8207508A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR74496B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE53001B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT72878B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112868A (en) * 1988-05-19 1992-05-12 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
US4943587A (en) * 1988-05-19 1990-07-24 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
US5068251A (en) * 1988-12-16 1991-11-26 Abbott Laboratories Lipoxygenase inhibiting compounds
US5212189A (en) * 1991-12-17 1993-05-18 Warner-Lambert Company Thiadiazole or oxadiazole analogs of fenamic acids containing substituted hydroxamate side chains as antiinflammatory agents
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6335329B1 (en) 1997-12-19 2002-01-01 Amgen Inc. Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US7053088B2 (en) 2002-05-22 2006-05-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
NZ537952A (en) 2002-08-08 2008-04-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7582631B2 (en) 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7429616B2 (en) 2005-07-15 2008-09-30 Board Of Regents, University Of Texas System Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US8232427B2 (en) 2006-03-29 2012-07-31 Novartis Ag Selective hydroxamate based MMP inhibitors
CA2654661C (en) 2006-06-26 2012-10-23 Amgen Inc. Compositions comprising modified lcat and use thereof for treating atherosclerosis
WO2008008493A2 (en) 2006-07-14 2008-01-17 Amgen Inc. Alkyne-substituted pyridone compounds and methods of use
AU2007275683B2 (en) 2006-07-20 2012-05-10 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
ES2344760T3 (es) 2006-07-20 2010-09-06 Amgen Inc. Compuestos de piridona sustituidos y metodo de uso.
CA2657258A1 (en) 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
EP2137186B1 (en) 2007-03-23 2016-01-27 Amgen Inc. Heterocyclic compounds and their uses
MX2010004929A (es) 2007-11-05 2010-05-27 Novartis Ag Derivados de 4-bencil-amino-1-carboxi-acil-piperidina como inhibidores de proteina de transferencia de colesterol-ester (cetp) utiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis.
PT2229356E (pt) 2007-12-03 2012-01-20 Novartis Ag Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
ES2524259T3 (es) 2008-03-24 2014-12-04 Novartis Ag Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
AU2009333214B2 (en) 2008-12-17 2013-09-26 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
WO2010085968A1 (en) 2008-12-30 2010-08-05 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use as hif-inhibitors
WO2010075869A1 (en) 2008-12-30 2010-07-08 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
PL2429995T3 (pl) 2009-05-15 2014-07-31 Novartis Ag Arylopirydyny jako inhibitory syntazy aldosteronu
KR20120041702A (ko) 2009-05-28 2012-05-02 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체
SG176009A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
AU2010266064A1 (en) 2009-06-25 2012-01-19 Amgen Inc. 4H - pyrido [1, 2 - a] pyrimidin - 4 - one derivatives as PI3 K inhibitors
CA2765819A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses as inhibitors of pi3 k activity
UY32742A (es) 2009-06-25 2010-12-31 Amgen Inc Compuestos heterocíclicos y sus usos
TW201111362A (en) 2009-06-25 2011-04-01 Amgen Inc Heterocyclic compounds and their uses
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
CA2771936A1 (en) 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
CN102686577A (zh) 2009-09-03 2012-09-19 阿勒根公司 作为酪氨酸激酶调节剂的化合物
CN102471310A (zh) 2009-09-04 2012-05-23 诺瓦提斯公司 用于治疗增生性疾病的联吡啶化合物
WO2011026904A1 (en) 2009-09-04 2011-03-10 Novartis Ag Pyrazinylpyridines useful for the treatment of proliferative diseases
MX2012002752A (es) 2009-09-04 2012-04-19 Novartis Ag Compuestos de heteroarilo como inhibidores de cinasa.
AR078770A1 (es) 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
JP5654608B2 (ja) 2009-11-17 2015-01-14 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリール−ピリジン誘導体
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5575913B2 (ja) 2009-11-30 2014-08-20 ノバルティス アーゲー アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
JP2013514989A (ja) 2009-12-18 2013-05-02 アムジエン・インコーポレーテツド 複素環式化合物およびその使用法
TW201132642A (en) 2009-12-21 2011-10-01 Novartis Ag Diaza-spiro[5.5]undecanes
US8742106B2 (en) 2009-12-21 2014-06-03 Novartis Ag Disubstituted heteroaryl-fused pyridines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
CA2798490A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors
WO2011143366A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
AU2011253003B2 (en) 2010-05-13 2014-05-01 Amgen Inc. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
US8946230B2 (en) 2010-05-13 2015-02-03 Amgen Inc. Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors
US20130090342A1 (en) 2010-06-17 2013-04-11 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
EP2582681A1 (en) 2010-06-17 2013-04-24 Novartis AG Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
MX2012014983A (es) 2010-06-30 2013-04-24 Amgen Inc Quinolinas como inhibidores pi3k.
MX2012015147A (es) 2010-06-30 2013-05-01 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
EP2588473A1 (en) 2010-06-30 2013-05-08 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
JP2013530236A (ja) 2010-07-01 2013-07-25 アムジエン・インコーポレーテツド Ｐｉ３ｋ活性の阻害剤としての複素環式化合物およびその用途
EP2588467A1 (en) 2010-07-01 2013-05-08 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
CA2803624A1 (en) 2010-07-02 2012-01-05 Jason A. Duquette Heterocyclic compounds and their use as inhibitors of pi3k activity
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
SG178311A1 (en) 2010-07-13 2012-03-29 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
BR112013000946B1 (pt) 2010-07-14 2020-09-08 Novartis Ag Compostos heterocíclicos agonistas de receptor de ip, seus usos, composição e combinação farmacêuticas
BR112013001516A2 (pt) 2010-07-22 2016-06-07 Novartis Ag compostos de tiofeno 2,3,5-trissubstituídos e empregos destes
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
PL2616465T3 (pl) 2010-09-13 2016-04-29 Novartis Ag Triazyno-oksadiazole
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AU2011305568B2 (en) 2010-09-20 2015-12-10 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
JP2013541591A (ja) 2010-11-04 2013-11-14 アムジエン・インコーポレーテツド 複素環化合物およびそれらの使用
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
EP2640715A1 (en) 2010-11-17 2013-09-25 Amgen Inc. Quinoline derivatives as pik3 inhibitors
US9090593B2 (en) 2010-12-09 2015-07-28 Amgen Inc. Bicyclic compounds as Pim inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2655368A1 (en) 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
JP2014500319A (ja) 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
US20130267526A1 (en) 2010-12-23 2013-10-10 Amgen, Inc. Heterocyclic compounds and their uses
CA2823665A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
CN103596569A (zh) 2011-01-13 2014-02-19 诺瓦提斯公司 用于治疗代谢障碍的bace-2抑制剂
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
US9321756B2 (en) 2011-03-22 2016-04-26 Amgen Inc. Azole compounds as PIM inhibitors
WO2012130306A1 (en) 2011-03-30 2012-10-04 Elara Pharmaceuticals Gmbh Bicyclic 2,3-dihyrdobenzazine compounds for use in therapy
WO2012130314A1 (en) 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
US20140221354A1 (en) 2011-03-31 2014-08-07 Emblem Technology Transfer Gmbh IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US9187486B2 (en) 2011-04-29 2015-11-17 Amgen Inc. Bicyclic pyridazine compounds as Pim inhibitors
US8778941B2 (en) 2011-06-24 2014-07-15 Amgen Inc. TRPM8 antagonists and their use in treatments
AU2012272895B2 (en) 2011-06-24 2015-01-22 Amgen Inc. TRPM8 antagonists and their use in treatments
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
JP2014530851A (ja) 2011-10-21 2014-11-20 ノバルティスアーゲー Ｐｉ３ｋモジュレータとしてのキナゾリン誘導体
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105057A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802581A1 (en) 2012-01-13 2014-11-19 Novartis AG 7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
WO2013142269A1 (en) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
MX2014011970A (es) 2012-04-04 2015-05-12 Amgen Inc Compuestos heterociclicos y sus usos.
TW201348199A (zh) 2012-05-04 2013-12-01 Novartis Ag 補體路徑調節劑及其用途
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
CN104520291A (zh) 2012-06-06 2015-04-15 Irm责任有限公司 用于调节egfr活性的化合物和组合物
UY34858A (es) 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10
CN104662015B (zh) 2012-06-20 2017-03-29 诺华股份有限公司 补体途径调节剂及其用途
JP6154897B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
JP6209605B2 (ja) 2012-06-28 2017-10-04 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
EA201590118A1 (ru) 2012-06-28 2015-04-30 Новартис Аг Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
EP2867227B1 (en) 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
ES2647124T3 (es) 2012-06-28 2017-12-19 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
CA2882724A1 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
US20150210717A1 (en) 2012-09-13 2015-07-30 Baden-Württemberg Stiftung Gmbh Specific inhibitors of protein p21 as therapeutic agents
JP2016507582A (ja) 2013-02-13 2016-03-10 ノバルティス アーゲー Ｉｐ受容体アゴニスト複素環式化合物
KR20150119109A (ko) 2013-02-14 2015-10-23 노파르티스 아게 Nep (중성 엔도펩티다제) 억제제로서의 치환된 비스페닐 부타노익 포스폰산 유도체
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
ES2761587T3 (es) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2016088082A1 (en) 2014-12-05 2016-06-09 Novartis Ag Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
US10407398B2 (en) 2015-03-24 2019-09-10 Helmholtz-Zentrum für Infektionsforschung GmbH Inhibitors of Pseudomonas aeruginosa LecB
ES2770128T3 (es) 2015-04-30 2020-06-30 Recordati Ag Derivados de pirazol tricíclicos condensados útiles para modular los receptores farnesoide x
CA2994859A1 (en) 2015-08-19 2017-02-23 Vivus, Inc. Pharmaceutical formulations
CN105418480B (zh) * 2015-11-16 2019-05-10 青岛大学 2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基)-n-羟基乙酰胺的制备和应用
CA3008485C (en) 2015-12-18 2023-08-01 Amgen Inc. Alkynyl dihydroquinoline sulfonamide compounds
MY197595A (en) 2015-12-18 2023-06-27 Amgen Inc Alkyl dihydroquinoline sulfonamide compounds
JP7161481B2 (ja) 2017-02-10 2022-10-26 ノバルティス アーゲー １－（４－アミノ－５－ブロモ－６－（１ｈ－ピラゾール－１－イル）ピリミジン－２－イル）－１ｈ－ピラゾール－４－オール及びがんの治療におけるその使用
WO2018229193A1 (en) 2017-06-14 2018-12-20 European Molecular Biology Laboratory Benzofuran amides and heteroaromatic analogues thereof for use in therapy
AU2018285831A1 (en) 2017-06-14 2019-12-19 European Molecular Biology Laboratory Bicyclic heteroaromatic amide compounds for use in therapy
CA3067070A1 (en) 2017-06-14 2018-12-20 European Molecular Biology Laboratory Bicyclic heteroaromatic urea or carbamate compounds for use in therapy
CN110997663A (zh) 2017-06-14 2020-04-10 欧洲分子生物学实验室 用于疗法的苯并呋喃脲或氨基甲酸酯及其杂芳族类似物
WO2019154859A1 (en) 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
IL276594B2 (en) 2018-02-06 2023-11-01 Univ Heidelberg FAP inhibitors
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
GB201811825D0 (en) 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
GB201813791D0 (en) 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
MX2021007157A (es) 2018-12-20 2021-08-16 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a.
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MX2021007104A (es) 2018-12-20 2021-08-11 Amgen Inc Inhibidores de kif18a.
MX2022001181A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
MX2022001296A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
JP2022542392A (ja) 2019-08-02 2022-10-03 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤としてのピリジン誘導体
US20220289724A1 (en) 2019-08-02 2022-09-15 Amgen Inc. Kif18a inhibitors
CA3159906A1 (en) 2019-11-05 2021-05-14 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Bivalent leca inhibitors targeting biofilm formation of pseudomonas aeruginosa
AU2021209418A1 (en) 2020-01-22 2022-07-21 Benevolentai Bio Limited Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds
CN115315254A (zh) 2020-01-22 2022-11-08 博善人工智能生物科技有限公司 药物组合物及其用途
BR112022020817A2 (pt) 2020-04-14 2023-03-07 Amgen Inc Inibidores de kif18a para tratamento de doenças neoplásicas
WO2021234181A1 (en) 2020-05-22 2021-11-25 Universität Heidelberg Use of fap inhibitor in a method of diagnosis
MX2022015856A (es) 2020-06-10 2023-01-24 Amgen Inc Compuestos de dihidroquinolin sulfonamida de ciclobutilo.
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
US20230227442A1 (en) 2020-06-10 2023-07-20 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
EP4204087A1 (en) 2020-08-26 2023-07-05 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Inhibitors of no production
TW202237095A (zh) 2020-12-03 2022-10-01 德商艾斯巴赫生物有限公司 Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性
CN116981479A (zh) 2020-12-17 2023-10-31 塔夫茨大学信托人 Fap激活的放射治疗诊断法以及与之相关的用途
CN118891042A (zh) 2021-10-29 2024-11-01 艾斯巴赫生物有限公司 与新型变构结合位点结合的病毒解旋酶抑制剂
WO2023161427A1 (en) 2022-02-24 2023-08-31 Eisbach Bio Gmbh Viral combination therapy
WO2023213833A1 (en) 2022-05-02 2023-11-09 Eisbach Bio Gmbh Use of alc1 inhibitors and synergy with parpi
WO2024022332A1 (en) 2022-07-26 2024-02-01 Shanghai Sinotau Biotech. Co., Ltd Fap inhibitors
US20250034117A1 (en) 2023-07-12 2025-01-30 HMNC Holding GmbH Deuterated 1,3 Dihydro -2H-indole-2-one derivatives
WO2025055942A1 (en) 2023-09-12 2025-03-20 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof
EP4590664A1 (en) 2023-09-12 2025-07-30 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof
WO2025088175A1 (en) 2023-10-25 2025-05-01 Eisbach Bio Gmbh Alc1 inhibitors for use in treating cancer by potentiating the effects of several classes of approved cancer drugs
WO2025088087A1 (en) 2023-10-25 2025-05-01 Eisbach Bio Gmbh A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers
WO2025093706A1 (en) 2023-10-31 2025-05-08 Eisbach Bio Gmbh Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1081993A (en) * 1963-04-17 1967-09-06 Ici Ltd Difluoramino compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3336194A (en) * 1963-04-30 1967-08-15 Merck & Co Inc Indolyl acid amides
US3417096A (en) * 1965-07-01 1968-12-17 Bristol Myers Co Certain 5(1-benzoyl-3-indolylmethyl) tetrazoles
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
DK143104C (da) * 1970-09-09 1981-11-09 Ciba Geigy Ag Analogifremgangsmaade til fremstilling af anilinophenylacetamidderivater eller salte deraf
US4206220A (en) * 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1081993A (en) * 1963-04-17 1967-09-06 Ici Ltd Difluoramino compounds

Also Published As

Publication number Publication date
GR74496B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-06-28
IE53001B1 (en) 1988-05-11
PT72878B (en) 1983-03-29
DK182081A (da) 1981-10-25
DE3171467D1 (en) 1985-08-29
IE810899L (en) 1981-10-24
EP0039051A2 (en) 1981-11-04
ES501573A0 (es) 1982-09-16
DK156717C (da) 1990-02-19
EP0039051B1 (en) 1985-07-24
DK156717B (da) 1989-09-25
EP0039051A3 (en) 1982-05-26
ES8207508A1 (es) 1982-09-16
ATE14423T1 (de) 1985-08-15
JPH04982B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-01-09
PT72878A (en) 1981-05-01

Similar Documents

Publication Publication Date Title
JPS56167643A (en) Mannich base hydroxamic acid precursor drug for improving transmission of non-steroid antiinflammatory
PT86343A (en) Process for the preparation of the morpholinoethylester of the mycophenolic acid and derivatives thereof
HU9300759D0 (en) Method for producing triazolo-pyridine derivatives and pharmaceutical preparatives containing said compounds as active substance
ES8302001A1 (es) Un procedimiento para la preparacion de nuevos derivados de cefalospirina.
ES8503686A1 (es) Procedimiento de preparar derivados de penicilina.
ES2013403A6 (es) Procedimiento para preparar derivados de cefem.
HUT46895A (en) Process for production of new 5-lipoxigenase bicyclic compounds with inhibiation effect
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
GB1062714A (en) -ß-(4'-acyloxy-4'-piperidyl)-ketones
DE3267188D1 (en) Hydroxybenzylamino-aryl compounds, process for preparing and pharmaceutical compositions containing the same
IE780901L (en) Tetrazolyl-piperidinyl amides
GB1464431A (en) Indolobenzazepine derivatives and a process for the manufacture thereof
MA18964A1 (fr) 2-aminoalkyl-5-pyridinols,procede pour leur preparation,compositions pharmaceutiques contenant ces composes et leurs utilisations therapeutiques
GB1434645A (en) Tetrazole coumarin derivatives
JPS55102586A (en) Preparation of novel penicillins